{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T21:07:32Z","timestamp":1777928852839,"version":"3.51.4"},"reference-count":104,"publisher":"SAGE Publications","issue":"13","license":[{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Lupus"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:p>Severe acute respiratory syndrome coronavirus (SARS-CoV-2), the virus causing Coronavirus disease 2019 (COVID-19), has had a huge impact on health services with a high mortality associated with complications including pneumonia and acute respiratory distress syndrome. Historical evidence suggests that Lupus patients have a higher incidence of several viral infections. This is likely due to a combination of immune dysfunction, immunosuppressive therapy and excess co-morbidities. In this context there has been concern that Lupus patients may be at a higher risk of developing COVID-19 and suffering a severe disease course. As a result, many Lupus patients have been advised to \u2018shield\u2019 by isolating from social contact in the hope that this will reduce the likelihood of infection. Early clinical data does not appear to show that the incidence of COVID-19 is higher in Lupus patients. Reassuringly, the clinical course of COVID-19 in Lupus does not generally seem to be more severe than in the general population. There has been huge interest in repurposing existing drugs as potential treatments, including several used to treat Lupus. Of these, corticosteroids and hydroxychloroquine are the most well researched so far. The current evidence suggests that the corticosteroid dexamethasone improves outcome for the sickest COVID-19 patients requiring respiratory support. Initial reports suggested that hydroxychloroquine could have a positive impact on the course of COVID-19, however larger prospective studies have not supported this. Janus kinase inhibitors, currently being investigated for efficacy in lupus, have been shown to have anti-viral effects in vitro and inhibiting the JAK-STAT pathway may dampen down the host hyper-inflammatory response. Several trials are ongoing to assess the outcome of the use of JAK inhibitors in COVID-19 positive patients. For most patients continuing with their existing therapies to prevent a lupus flare or adverse events associated with sudden corticosteroid withdrawal is important whilst an Individualised risk assessment remains vital.<\/jats:p>","DOI":"10.1177\/0961203320961848","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T02:19:14Z","timestamp":1602814754000},"page":"1661-1672","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":17,"title":["Clinical management of Lupus patients during the COVID-19 pandemic"],"prefix":"10.1177","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3121-8569","authenticated-orcid":false,"given":"Alice","family":"Mason","sequence":"first","affiliation":[{"name":"Rheumatology Department, University Hospital Southampton NHS Foundation Trust, Southampton, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Rose","sequence":"additional","affiliation":[{"name":"Rheumatology Department, University Hospital Southampton NHS Foundation Trust, Southampton, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8233-6602","authenticated-orcid":false,"given":"Christopher J","family":"Edwards","sequence":"additional","affiliation":[{"name":"Rheumatology Department, University Hospital Southampton NHS Foundation Trust, Southampton, UK"},{"name":"MSK Research Unit, NIHR Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,10,15]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"WHO Europe. WHO announces COVID-19 outbreak a pandemic Geneva: WHO Europe; 2020. Available from: https:\/\/www.euro.who.int\/en\/health-topics\/health-emergencies\/coronavirus-covid-19\/news\/news\/2020\/3\/who-announces-covid-19-outbreak-a-pandemic]. Accessed 5 July 2020."},{"key":"e_1_3_3_3_2","doi-asserted-by":"crossref","unstructured":"Grasselli G et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region Italy. Jama 2020; 323(16): 1574\u20131581.","DOI":"10.1001\/jama.2020.4031"},{"key":"e_1_3_3_4_2","doi-asserted-by":"crossref","unstructured":"Richardson S et al. Presenting Characteristics Comorbidities and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. Jama 2020; 323(20): 2052\u20132059.","DOI":"10.1001\/jama.2020.6775"},{"key":"e_1_3_3_5_2","doi-asserted-by":"crossref","unstructured":"Merad M and Martin JC Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nature Reviews Immunology 2020; 20(6): 355\u2013362.","DOI":"10.1038\/s41577-020-0331-4"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203313502571"},{"key":"e_1_3_3_7_2","doi-asserted-by":"crossref","unstructured":"Funk GA et al. Viral dynamics in transplant patients: implications for disease. The Lancet Infectious Diseases 2007; 7(7): 460\u2013472.","DOI":"10.1016\/S1473-3099(07)70159-7"},{"key":"e_1_3_3_8_2","doi-asserted-by":"crossref","unstructured":"Yen EY et al. 46-Year Trends in Systemic Lupus Erythematosus Mortality in the United States 1968 to 2013: A Nationwide Population-Based Study. Ann Intern Med 2017; 167(11): 777\u2013785.","DOI":"10.7326\/M17-0102"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-46039-5"},{"key":"e_1_3_3_10_2","doi-asserted-by":"crossref","unstructured":"Danza A and Ruiz-Irastorza G. Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies. Lupus 2013; 22(12): 1286\u20131294.","DOI":"10.1177\/0961203313493032"},{"key":"e_1_3_3_11_2","doi-asserted-by":"crossref","unstructured":"Bosch X et al. Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients. Lupus 2006; 15(9): 584\u2013589.","DOI":"10.1177\/0961203306071919"},{"key":"e_1_3_3_12_2","doi-asserted-by":"crossref","unstructured":"Doaty S et al. Infection and Lupus: Which Causes Which? Curr Rheumatol Rep 2016; 18(3): 13.","DOI":"10.1007\/s11926-016-0561-4"},{"key":"e_1_3_3_13_2","doi-asserted-by":"crossref","unstructured":"Nagasawa K et al. High incidence of herpes zoster in patients with systemic lupus erythematosus: an immunological analysis. Annals of the Rheumatic Diseases 1990; 49(8): 630\u2013633.","DOI":"10.1136\/ard.49.8.630"},{"key":"e_1_3_3_14_2","doi-asserted-by":"crossref","unstructured":"Li T.-H. et al. Risk of severe herpes simplex virus infection in systemic lupus erythematosus: analysis of epidemiology and risk factors analysis in Taiwan. Annals of the Rheumatic Diseases 2019; 78(7): 941\u2013946.","DOI":"10.1136\/annrheumdis-2018-214844"},{"key":"e_1_3_3_15_2","doi-asserted-by":"crossref","unstructured":"Zhao M et al. DNA methylation and mRNA and microRNA expression of SLE CD4+ T cells correlate with disease phenotype. Journal of Autoimmunity 2014; 54: 127\u2013136.","DOI":"10.1016\/j.jaut.2014.07.002"},{"key":"e_1_3_3_16_2","doi-asserted-by":"crossref","unstructured":"Sawalha AH et al. Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients. Clin Immunol 2020; 215: 108410.","DOI":"10.1016\/j.clim.2020.108410"},{"key":"e_1_3_3_17_2","doi-asserted-by":"crossref","unstructured":"James JA Sestak AL and Vista ES. SLE and infections. In Dubois' Lupus erythematosus and related syndromes: eighth edition. Chapter 45. 2012.","DOI":"10.1016\/B978-1-4377-1893-5.00045-5"},{"key":"e_1_3_3_18_2","doi-asserted-by":"crossref","unstructured":"COVID -19 Global Rheumatology Alliance. Data from The COVID-19 Global Rheumatology Alliance Global Registry: COVID -19 Global Rheumatology Alliance; 2020. Available from: https:\/\/rheum-covid.org\/updates\/combined-data.html (accessed 2 August 2020).","DOI":"10.1016\/S2665-9913(20)30125-9"},{"key":"e_1_3_3_19_2","doi-asserted-by":"crossref","unstructured":"Helmick CG et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008; 58(1): 15\u201325.","DOI":"10.1002\/art.23177"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217871"},{"key":"e_1_3_3_21_2","doi-asserted-by":"crossref","unstructured":"Konig MF et al. Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19. Annals of the Rheumatic Diseases 2020; 79(10): 1386\u20131388.","DOI":"10.1136\/annrheumdis-2020-217690"},{"key":"e_1_3_3_22_2","doi-asserted-by":"crossref","unstructured":"Sanchez-Piedra C et al. Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. Annals of the Rheumatic Diseases 2020; 79(7): 988\u2013990.","DOI":"10.1136\/annrheumdis-2020-217948"},{"key":"e_1_3_3_23_2","doi-asserted-by":"crossref","unstructured":"Mathian A et al. Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. Ann Rheum Dis 2020; 79(6): 837\u2013839.","DOI":"10.1136\/annrheumdis-2020-217875"},{"key":"e_1_3_3_24_2","doi-asserted-by":"crossref","unstructured":"Gianfrancesco MA et al. Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. Lancet Rheumatol 2020; 2(5): e250\u2013e253.","DOI":"10.1016\/S2665-9913(20)30095-3"},{"key":"e_1_3_3_25_2","doi-asserted-by":"crossref","unstructured":"Li X et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 2020; 146(1): 110\u2013118.","DOI":"10.1016\/j.jaci.2020.04.006"},{"key":"e_1_3_3_26_2","doi-asserted-by":"crossref","unstructured":"Michelena X et al. Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs. Seminars in Arthritis and Rheumatism 2020; 50(4): 564\u2013570.","DOI":"10.1016\/j.semarthrit.2020.05.001"},{"key":"e_1_3_3_27_2","doi-asserted-by":"crossref","unstructured":"Monti S et al. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Annals of the Rheumatic Diseases 2020; 79(5): 667\u2013668.","DOI":"10.1136\/annrheumdis-2020-217424"},{"key":"e_1_3_3_28_2","unstructured":"University of Oxford. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19 Oxford: University of Oxford; 2020. Available from: https:\/\/www.recoverytrial.net\/news\/low-cost-dexamethasone-reduces-death-by-up-to-one-third-in-hospitalised-patients-with-severe-respiratory-complications-of-covid-19"},{"key":"e_1_3_3_29_2","doi-asserted-by":"crossref","unstructured":"Ruiz-Irastorza G et al. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther 2009; 11(4): R109.","DOI":"10.1186\/ar2764"},{"key":"e_1_3_3_30_2","doi-asserted-by":"crossref","unstructured":"Landew\u00e9 RB et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Annals of the Rheumatic Diseases 2020; 79(7): 851\u2013858.","DOI":"10.1136\/annrheumdis-2020-217877"},{"key":"e_1_3_3_31_2","unstructured":"National Institute for Health and Care Excellence. COVID-19 rapid guideline: rheumatological autoimmune inflammatory and metabolic bone disorders. NICE guideline [NG167] London: NICE; 2020. Available from: https:\/\/www.nice.org.uk\/guidance\/NG167."},{"key":"e_1_3_3_32_2","unstructured":"American College of Rheumatology. COVID-19 clinical guidance for patients with rheumatic diseases www.rheumatology.org\/Portals\/0\/Files\/ACR-COVID-19-Clinical-Guidance-Summary-Patients-with-Rheumatic-Diseases.pdf (2020 accessed 20 April 2020)"},{"key":"e_1_3_3_33_2","doi-asserted-by":"crossref","unstructured":"Ruiz-Irastorza G et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010; 69(1): 20\u201328.","DOI":"10.1136\/ard.2008.101766"},{"key":"e_1_3_3_34_2","doi-asserted-by":"crossref","unstructured":"Savarino A et al. Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis 2003; 3(11): 722\u2013727.","DOI":"10.1016\/S1473-3099(03)00806-5"},{"key":"e_1_3_3_35_2","doi-asserted-by":"crossref","unstructured":"Sis\u00f3 A et al. Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. Lupus 2008; 17(4): 281\u2013288.","DOI":"10.1177\/0961203307086503"},{"key":"e_1_3_3_36_2","doi-asserted-by":"crossref","unstructured":"Keyaerts E et al. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun 2004; 323(1): 264\u2013268.","DOI":"10.1016\/j.bbrc.2004.08.085"},{"key":"e_1_3_3_37_2","doi-asserted-by":"crossref","unstructured":"Vincent MJ et al. (2005). Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2: 69.","DOI":"10.1186\/1743-422X-2-69"},{"key":"e_1_3_3_38_2","doi-asserted-by":"crossref","unstructured":"Liu J et al. Hydroxychloroquine a less toxic derivative of chloroquine is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020; 6: 16.","DOI":"10.1038\/s41421-020-0156-0"},{"key":"e_1_3_3_39_2","doi-asserted-by":"crossref","unstructured":"Mercuro NJ et al. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 2020; 5(9): 1036\u20131041.","DOI":"10.1001\/jamacardio.2020.1834"},{"key":"e_1_3_3_40_2","doi-asserted-by":"crossref","unstructured":"Hooks M Bart B Vardeny O Westanmo A and Adabag S. Effects of hydroxychloroquine treatment on QT interval. Heart Rhythm. 28 June 2020.","DOI":"10.1016\/j.hrthm.2020.06.029"},{"key":"e_1_3_3_41_2","doi-asserted-by":"crossref","unstructured":"Gautret P et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020; 56(1): 105949.","DOI":"10.1016\/j.ijantimicag.2020.105949"},{"key":"e_1_3_3_42_2","doi-asserted-by":"crossref","unstructured":"Gautret P et al. (2020). Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med Infect Dis 34: 101663.","DOI":"10.1016\/j.tmaid.2020.101663"},{"key":"e_1_3_3_43_2","doi-asserted-by":"crossref","unstructured":"Molina JM et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect 2020; 50(4): 384.","DOI":"10.1016\/j.medmal.2020.03.006"},{"key":"e_1_3_3_44_2","doi-asserted-by":"crossref","unstructured":"Million M et al. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille France. Travel Med Infect Dis 2020; 35: 101738.","DOI":"10.1016\/j.tmaid.2020.101738"},{"key":"e_1_3_3_45_2","doi-asserted-by":"crossref","unstructured":"Geleris J et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med 2020; 382(25): 2411\u20132418.","DOI":"10.1056\/NEJMoa2012410"},{"key":"e_1_3_3_46_2","doi-asserted-by":"crossref","unstructured":"Mah\u00e9vas M Tran V-T Roumier M Chabrol A Paule R Guillaud C et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ 2020; 369.","DOI":"10.1136\/bmj.m1844"},{"key":"e_1_3_3_47_2","doi-asserted-by":"crossref","unstructured":"Magagnoli J et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. medRxiv 2020.","DOI":"10.1101\/2020.04.16.20065920"},{"key":"e_1_3_3_48_2","unstructured":"Chen J et al. [A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19]. Zhejiang Da Xue Xue Bao Yi Xue Ban 2020; 49(2): 215\u2013219."},{"key":"e_1_3_3_49_2","unstructured":"University of Oxford. No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19 Oxford: University of Oxford; 2020. Available from: https:\/\/www.recoverytrial.net\/news\/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19."},{"key":"e_1_3_3_50_2","doi-asserted-by":"crossref","unstructured":"Tang W et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label randomised controlled trial. Bmj 2020; 369: m1849.","DOI":"10.1136\/bmj.m1849"},{"key":"e_1_3_3_51_2","doi-asserted-by":"crossref","unstructured":"Boulware DR et al. (2020). A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med 383(6): 517\u2013525.","DOI":"10.1056\/NEJMoa2016638"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-04446-4"},{"key":"e_1_3_3_53_2","doi-asserted-by":"crossref","unstructured":"Lother SA et al. Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic randomized-controlled trial. Can J Anaesth 2020; 67(9): 1201\u20131211.","DOI":"10.1007\/s12630-020-01684-7"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-04400-4"},{"key":"e_1_3_3_55_2","doi-asserted-by":"crossref","unstructured":"Wallace DJ et al. (2018). Baricitinib for systemic lupus erythematosus: a double-blind randomised placebo-controlled phase 2 trial. Lancet 392(10143): 222\u2013231.","DOI":"10.1016\/S0140-6736(18)31363-1"},{"key":"e_1_3_3_56_2","doi-asserted-by":"crossref","unstructured":"Pu SY et al. Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment. Antiviral Res 2018; 155: 67\u201375.","DOI":"10.1016\/j.antiviral.2018.05.001"},{"key":"e_1_3_3_57_2","doi-asserted-by":"crossref","unstructured":"Bekerman E et al. Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects. J Clin Invest 2017; 127(4): 1338\u20131352.","DOI":"10.1172\/JCI89857"},{"key":"e_1_3_3_58_2","doi-asserted-by":"crossref","unstructured":"Stebbing J et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis 2020; 20(4): 400\u2013402.","DOI":"10.1016\/S1473-3099(20)30132-8"},{"key":"e_1_3_3_59_2","unstructured":"Cantini F. Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label Pilot Study. Clinical Trials 2020."},{"key":"e_1_3_3_60_2","unstructured":"Barrett L. Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients. Clinical Trials 2020."},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.8630"},{"key":"e_1_3_3_62_2","doi-asserted-by":"crossref","unstructured":"D'Silva KM et al. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US \u2018hot spot\u2019. Annals of the Rheumatic Diseases 2020; 79(9): 1156-1162.","DOI":"10.1136\/annrheumdis-2020-217888"},{"key":"e_1_3_3_63_2","doi-asserted-by":"crossref","unstructured":"Pineau C Lee C Ramsey-Goldman R and Clarke A Bernatsky S. The second hit: comorbidities in systemic lupus erythematosus. Future Rheumatology 2007; 2: 497\u2013506.","DOI":"10.2217\/17460816.2.5.497"},{"key":"e_1_3_3_64_2","doi-asserted-by":"crossref","unstructured":"Hippisley-Cox J et al. (2017). Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. Bmj 357: j2099.","DOI":"10.1136\/bmj.j2099"},{"key":"e_1_3_3_65_2","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez M et al. A multiethnic multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. Arthritis Rheum 2007; 57(4): 576\u2013584.","DOI":"10.1002\/art.22672"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203306072311"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.12688\/wellcomeopenres.15922.2"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30228-9"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.6548"},{"key":"e_1_3_3_70_2","unstructured":"COVID-19 and racial\/ethnic disparities| health disparities | JAMA | JAMA network. https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2766098 (accessed 20 June 2020)."},{"key":"e_1_3_3_71_2","unstructured":"COVID-19 hospitalizations. https:\/\/gis.cdc.gov\/grasp\/COVIDNet\/COVID19_5.html (accessed 20 June 2020)."},{"key":"e_1_3_3_72_2","doi-asserted-by":"crossref","unstructured":"Niedzwiedz CL et al. Ethnic and socioeconomic differences in SARS-CoV-2 infection: prospective cohort study using UK Biobank. BMC Med 2020; 18(1): 160.","DOI":"10.1186\/s12916-020-01640-8"},{"key":"e_1_3_3_73_2","unstructured":"Office for National Statistics. Coronavirus-related deaths by ethnic group England and Wales methodology. Coronavirus-related deaths by ethnic group England and Wales methodology www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/deaths\/methodologies\/coronavirusrelateddeathsbyethnicgroupenglandandwalesmethodology (accessed 20 June 2020)."},{"key":"e_1_3_3_74_2","doi-asserted-by":"crossref","unstructured":"Williamson EJ et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020; 584(7821): 430\u2013436.","DOI":"10.1038\/s41586-020-2521-4"},{"key":"e_1_3_3_75_2","doi-asserted-by":"crossref","unstructured":"Raisi-Estabragh Z et al. Greater risk of severe COVID-19 in Black Asian and Minority Ethnic populations is not explained by cardiometabolic socioeconomic or behavioural factors or by 25(OH)-vitamin D status: study of 1326 cases from the UK Biobank. J Public Health (Oxf) 2020; 42(3): 451\u2013460.","DOI":"10.1093\/pubmed\/fdaa095"},{"key":"e_1_3_3_76_2","unstructured":"Patients with lupus are not protected from COVID-19|annals of the rheumatic diseases. https:\/\/ard.bmj.com\/content\/early\/2020\/05\/22\/annrheumdis-2020-217656.full#ref-3 (accessed 20 June 2020)."},{"key":"e_1_3_3_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2014.01.006"},{"key":"e_1_3_3_78_2","doi-asserted-by":"publisher","DOI":"10.5152\/eurjrheum.2015.0085"},{"key":"e_1_3_3_79_2","doi-asserted-by":"publisher","DOI":"10.1053\/sarh.2002.28303"},{"key":"e_1_3_3_80_2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203317731532"},{"key":"e_1_3_3_81_2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203316640912"},{"key":"e_1_3_3_82_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2013656"},{"key":"e_1_3_3_83_2","article-title":"Frequency of lupus anticoagulant in Covid\u201019 patients.","author":"Harzallah I","year":"2020","unstructured":"Harzallah I, Debliquis A, Dr\u00e9nou B. Frequency of lupus anticoagulant in Covid\u201019 patients. J Thromb Haemost, www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7283640\/ (accessed 20 June 2020).","journal-title":"J Thromb Haemost"},{"key":"e_1_3_3_84_2","article-title":"High frequency of antiphospholipid antibodies in critically-ill COVID-19 patients: a link with hypercoagulability?","author":"de Chambrun MP","year":"2020","unstructured":"de Chambrun MP, Frere C, Miyara M, et\u00a0al. High frequency of antiphospholipid antibodies in critically-ill COVID-19 patients: a link with hypercoagulability? J Intern Med 2020, https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1111\/joim.13126 (accessed 20 June 2020).","journal-title":"J Intern Med"},{"key":"e_1_3_3_85_2","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14893"},{"key":"e_1_3_3_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2020.05.017"},{"key":"e_1_3_3_87_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26135"},{"key":"e_1_3_3_88_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2020.04.013"},{"key":"e_1_3_3_89_2","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14768"},{"key":"e_1_3_3_90_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16725"},{"key":"e_1_3_3_91_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-323586"},{"key":"e_1_3_3_92_2","article-title":"Brief report: anti-phospholipid antibodies in critically ill patients with coronavirus disease 2019 (COVID-19).","author":"Xiao M","year":"2020","unstructured":"Xiao M, Zhang Y, Zhang S, et\u00a0al. Brief report: anti-phospholipid antibodies in critically ill patients with coronavirus disease 2019 (COVID-19). Arthritis Rheumatol, https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1002\/art.41425 (2020, accessed 20 June 2020).","journal-title":"Arthritis Rheumatol"},{"key":"e_1_3_3_93_2","first-page":"e8408","article-title":"Coronavirus disease 2019 (COVID-19) infection associated with antiphospholipid antibodies and four-extremity deep vein thrombosis in a previously healthy female","volume":"12","author":"Sung J","year":"2020","unstructured":"Sung J, Anjum S. Coronavirus disease 2019 (COVID-19) infection associated with antiphospholipid antibodies and four-extremity deep vein thrombosis in a previously healthy female. Cureus 2020; 12: e8408.","journal-title":"Cureus"},{"key":"e_1_3_3_94_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2007575"},{"key":"e_1_3_3_95_2","doi-asserted-by":"crossref","unstructured":"Sieiro Santos C et al. Antiphospholipid antibodies in patient with acute lower member ischemia and pulmonary thromboembolism as a result of infection by SARS-CoV2. Clinical Rheumatology 2020; 39(7): 2105\u20132106.","DOI":"10.1007\/s10067-020-05194-1"},{"key":"e_1_3_3_96_2","doi-asserted-by":"crossref","unstructured":"Zayet S Klopfenstein T Kov\u00e0cs R Stancescu S and Hagenk\u00f6tter B. Acute Cerebral Stroke with Multiple Infarctions and COVID-19 France 2020. Emerg Infect Dis 2020; 26(9):2258\u20132260.","DOI":"10.3201\/eid2609.201791"},{"key":"e_1_3_3_97_2","doi-asserted-by":"crossref","unstructured":"Helms J et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 2020; 46(6): 1089\u20131098.","DOI":"10.1007\/s00134-020-06062-x"},{"key":"e_1_3_3_98_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2020.05.001"},{"key":"e_1_3_3_99_2","unstructured":"COVID-19 and aPL Ab - Hematology.org www.hematology.org:443\/covid-19\/covid-19-and-apl-ab (2020 accessed 27 June 2020)."},{"key":"e_1_3_3_100_2","unstructured":"Antithrombotic therapy|coronavirus disease COVID-19. COVID-19 treatment guidelines. https:\/\/www.covid19treatmentguidelines.nih.gov\/antithrombotic-therapy\/ (2020 accessed 26 June 2020)."},{"key":"e_1_3_3_101_2","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvaa036"},{"key":"e_1_3_3_102_2","unstructured":"Thromboprophylaxis in COVID-19 patients. https:\/\/handbook.ggcmedicines.org.uk\/guidelines\/covid-19-coronavirus\/thromboprophylaxis-in-covid-19-patients\/ (2020 accessed 28 June 2020)."},{"key":"e_1_3_3_103_2","unstructured":"British Thoracic Society. BTS guidance on venous thromboembolic disease in patients with COVID-19. file:\/\/\/C:\/Users\/emily\/Downloads\/BTS%20Guidance%20on%20Venous%20Thromboembolic%20Disease%20in%20patients%20with%20COVID-19%20(2).pdf (2020 accessed 28 June 2020)."},{"key":"e_1_3_3_104_2","unstructured":"Drage S West J Phillips B. Venous thromboembolism (VTE) prophylaxis and treatment in COVID-19 patients in critical care areas www.bsuh.nhs.uk\/library\/wp-content\/uploads\/sites\/8\/2020\/04\/BSUH-Crit-care-Anticoag-in-COVID-guidelinesv1.4-2170420.pdf (2020 accessed 28 June 2020)."},{"key":"e_1_3_3_105_2","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2020.1792778"}],"container-title":["Lupus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0961203320961848","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0961203320961848","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0961203320961848","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:23:03Z","timestamp":1777677783000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0961203320961848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":104,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1177\/0961203320961848"],"URL":"https:\/\/doi.org\/10.1177\/0961203320961848","relation":{},"ISSN":["0961-2033","1477-0962"],"issn-type":[{"value":"0961-2033","type":"print"},{"value":"1477-0962","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,15]]}}}